Home/News/Retatrutide

Metabolic Research

Triple Agonist

Retatrutide: The Triple-Agonist Deep Dive

Retatrutide (LY3437943) is an investigational once-weekly peptide from Eli Lilly that activates three metabolic receptors at once — GIP, GLP-1, and glucagon. In Phase 2 trials it produced the largest weight loss ever reported for a drug, approaching surgical territory. This article traces its history, the trial data, the FDA pathway, exactly how it works, and what we do and don't yet know about its downstream effects.

Investigational compound — research use only. Retatrutide is not FDA approved and is not available as a prescription medicine. Anything sold under this name outside a clinical trial is unapproved and unregulated. This article is educational and is not medical advice.

Drug class

Triple agonist (GIP/GLP-1/glucagon)

Developer

Eli Lilly (LY3437943)

FDA approved

No — Phase 3 (investigational)

Route

Once-weekly subcutaneous

History & Discovery

2010s

The incretin race begins

Following the success of GLP-1 receptor agonists, Eli Lilly pursued multi-receptor 'unimolecular' agonists — single peptides engineered to hit several metabolic receptors at once. Tirzepatide (dual GIP/GLP-1) was the first major success and set the stage for adding a third target.

2020–2022

Adding glucagon

Researchers had long known glucagon receptor agonism increases energy expenditure and promotes hepatic fat oxidation, but glucagon alone raises blood sugar. Combining it with GLP-1 (which lowers glucose) created a path to harness glucagon's metabolic benefits safely. Retatrutide (LY3437943) emerged as Lilly's triple-agonist candidate.

2023

Phase 2 results stun the field

Phase 2 data published in the New England Journal of Medicine reported mean weight loss of up to ~24% at 48 weeks at the 12 mg dose — the largest weight reduction reported for any pharmacological agent at the time, approaching the range of bariatric surgery.

2023–present

TRIUMPH Phase 3 program

Lilly launched the large TRIUMPH Phase 3 trial program spanning obesity, type 2 diabetes, knee osteoarthritis, and metabolic dysfunction-associated steatohepatitis (MASH). Results from these trials will determine the regulatory path.

Clinical Trial Evidence

Phase 1 (Coskun et al., 2022)

Phase 1

N: Healthy and T2D adultsDuration: Multiple ascending dose

Established safety, pharmacokinetics supporting once-weekly dosing, and early signals of dose-dependent weight loss and glucose lowering. Confirmed engagement of all three receptors.

Phase 2 Obesity (Jastreboff et al., NEJM 2023)

Phase 2

N: 338 adults with obesityDuration: 48 weeks

Mean weight reduction of −17.5% (8 mg) and up to −24.2% (12 mg) vs −2.1% placebo. A substantial fraction of participants at the top dose lost ≥25% of body weight — results not previously seen with pharmacotherapy.

Phase 2 Type 2 Diabetes (Rosenstock et al., Lancet 2023)

Phase 2

N: 281 adults with T2DDuration: 36 weeks

Robust HbA1c reductions (up to ~2.0%) alongside weight loss up to ~16.9%, demonstrating dual metabolic benefit in diabetes.

Phase 2 MASLD/Liver Fat (Sanyal et al., 2024)

Phase 2

N: Adults with metabolic liver diseaseDuration: 48 weeks

Marked reductions in liver fat content (a high proportion of participants achieving normalization), supporting the glucagon component's role in hepatic fat metabolism.

FDA Approval Process

Current status: investigational

As of this writing retatrutide is NOT FDA approved. It is an investigational compound being evaluated in Phase 3 trials. It cannot be legally marketed or prescribed as a treatment, and any material sold as 'retatrutide' outside a clinical trial is unapproved and unregulated.

Phase 3 TRIUMPH program

FDA approval of a new molecular entity requires successful Phase 3 trials demonstrating efficacy and safety in the target population, plus long-term safety data. Lilly's TRIUMPH program is designed to provide this evidence base across obesity, diabetes, and related conditions.

What approval would require

A New Drug Application (NDA) submission with full trial data, manufacturing/quality (CMC) documentation, and a risk evaluation. The FDA reviews efficacy versus risk, may convene advisory committees, and — given the drug class — would scrutinize cardiovascular safety, thyroid C-cell findings, and gastrointestinal tolerability.

Mechanism of Action

GLP-1 receptor agonism

Like semaglutide, retatrutide activates GLP-1 receptors — enhancing glucose-dependent insulin secretion, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake.

GIP receptor agonism

Glucose-dependent insulinotropic polypeptide (GIP) receptor activation complements GLP-1, improving insulin response and (as seen with tirzepatide) appearing to enhance weight loss and tolerability through central and adipose effects.

Glucagon receptor agonism — the differentiator

The third arm is what sets retatrutide apart. Glucagon receptor activation increases resting energy expenditure (the body burns more calories) and promotes hepatic lipolysis and fat oxidation — directly addressing fatty liver. The GLP-1/GIP components offset glucagon's tendency to raise blood glucose, allowing the metabolic upside without hyperglycemia.

Net effect

The combination reduces calorie intake (appetite suppression) while simultaneously increasing calorie expenditure (glucagon) — a two-sided energy-balance mechanism that may explain the unusually large weight-loss magnitude observed in trials.

Downstream Effects

Known / Documented

Dose-dependent weight loss up to ~24% in Phase 2 (largest reported for pharmacotherapy)
Significant HbA1c reduction in type 2 diabetes
Marked reduction in liver fat content (MASLD/MASH research)
Improvements in blood pressure and lipid markers alongside weight loss
Dose-dependent gastrointestinal effects: nausea, vomiting, diarrhea, constipation
Modest increases in heart rate (a class effect of incretin/glucagon agents)

Speculative / Under Study

May become the most powerful weight-loss pharmacotherapy if Phase 3 confirms Phase 2 magnitude
Potential best-in-class effect on hepatic fat via the glucagon arm (MASH research ongoing)
Under study for knee osteoarthritis pain (likely weight- and inflammation-mediated)
Theoretical cardiometabolic benefit pending dedicated cardiovascular outcomes data
Long-term safety of sustained glucagon agonism in humans is not yet established
Durability of weight loss and rebound after discontinuation remain to be characterized